A recent phase 2 randomized trial was conducted comparing 2 doses of estrogen (6 mg and 30 mg) in patients with metastatic disease resistant to aromatase inhibitor therapy [35]. This evidence concerns the gene CYP19A1 and metastatic neoplasm.